Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.33 USD
Change Today -0.02 / -0.08%
Volume 277.8K
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

301 Penobscot Drive

Redwood City, CA 94063

United States

Phone: 650-556-9300

Fax:

Genomic Health, Inc., a global healthcare company, provides genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer. The company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The company offers Oncotype DX tests as clinical laboratory services, utilizing existing technologies, such as RT-PCR, and information technologies and optimizes and integrates them into new processes. Its Oncotype DX cancer tests analyze the expression levels of multiple genes across multiple biological pathways to predict cancer aggressiveness. The company’s research and development activities are focused on developing a pipeline of tests to optimize the treatment of urologic cancers, including bladder and kidney cancers, as well as additional treatment decisions in breast, colon and prostate cancers. As of December 31, 2014, approximately 19,000 physicians in approximately 70 countries had ordered approximately 500,000 Oncotype DX tests. The company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Patents and Proprietary Technology As of December 31, 2014, the company had 39 issued patents in the United States and 85 issued patents outside of the United States covering genes and methods that are components of the Oncotype DX breast, colon and prostate cancer tests or research methods and platform technologies. For patents issued by the European Patent Office, the company validated each patent in key European Union countries. In addition, the company has various pending patent applications in the United States and in other countries, including provisional and non-provisional filings. The company’s issued U.S. patents expire at various times between 2023 and 2032. Some of these U.S. patent applications also have corresponding pending or granted applications under the Patent Cooperation Treaty in Canada, Europe, Japan, Australia and other jurisdictions. In these patent applications, it has either sole or joint ownership positions. Agreements The company licenses from Roche Molecular Systems, Inc., on a non-exclusive basis, a number of U.S. patents claiming nucleic acid amplification processes known as PCR, homogeneous PCR, and RT-PCR. It uses these processes in its research and development activities and in the processing of its Oncotype DX tests. Research and Development Expenses As of December 31, 2014, the company’s research and development expenses included $56.1 million. Competition The company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies, such as, GE Healthcare, a business unit of General Electric Company; Hologic, Inc.; Myriad Genetics, Inc.; NanoString Technologies, Inc.; Novartis AG; Qiagen N.V.; and Response Genetics, Inc. The company faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. Regulation As a clinical reference laboratory, the company is required to hold certain federal, state and local licenses, certifications and permits to conduct its business. Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the company is required to hold a certificate applicable to the type of work it performs and to comply with standards covering personnel, facilities administration, quality systems and proficiency testing. Clinical laboratory tests like the company’s Oncotype DX tests are regulated under CLIA, as administered by the Centers for Medicare and Medicaid Services, as well as by applicable state laws. Diagnostic that are sold and distributed through interstate commerce are regulated as medical devices by the Food and Drug Administration. The company is subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar restrictions under California's Physician Ownership and Referral Act. History Genomic Health, Inc. was founded in 2000. The company was incorporated in Delaware in 2000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $26.33 USD -0.02

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $14.09 USD +0.18
Enzo Biochem Inc $2.92 USD +0.03
Foundation Medicine Inc $23.65 USD +0.72
NanoString Technologies Inc $14.86 USD +0.21
NeoGenomics Inc $6.48 USD +0.54
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.